naloxone hydrochloride · Harm Reduction Therp · NDA 217722
Rivive
Earliest generic entry, as listed
11 May 2032
Blocked by patent: US 11020343, US 11806428, US 12458591.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11020343 | use U-3671 | 11 May 2032 |
| US 11806428 | product | 11 May 2032 |
| US 12458591 | use U-3671 | 11 May 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217722 · 001 · RLD | spray, metered, nasal | 3MG/SPRAY | 11 May 2032 |